Shanghai, China · Founded 2017 · Privately Held (backing)
Developer of molecular diagnosis technology designed for precision cancer medicine. Ruijing Bio is based in Shanghai, China and was founded in 2017. Its last reported valuation was $109 million in Apr 2022. It has raised $44 million.
Last reported valuation
$109.1M
Oct 2026
Priced at
—
Total raised
$44.0M
Last round
—
Cap table — not yet on record
Ruijing Bio's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Ruijing Bio with a free account
·Watch Ruijing Bio: the Monday email on marks, rounds and moves
